EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Anna Solini, Domenico Tricò, Stefano Del Prato

Diabetologia · 2023-10 · 66 (10) · 1820-1831

DOI: 10.1007/s00125-023-05973-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetologia, online erschienen am 05.08.2023. Verfasst von Anna Solini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Pisa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and non-glycaemic effects, including improved insulin secretion and action, body-weight loss, blood-pressure lowering and improved lipid profile, as well as via direct effects on the heart and vasculature. These actions are likely combined with anti-inflammatory and antioxidant properties that translate into robust and consistent reductions in atherothrombotic events, particularly in people with type 2 diabetes and established atherosclerotic CVD. GLP-1RAs may also have an impact on obesity and chronic kidney disease, conditions for which cardiovascular risk-reducing options are limited. The available evidence has prompted professional and medical societies to recommend GLP-1RAs for mitigation of the cardiovascular risk in people with type 2 diabetes. This review summarises the clinical evidence for cardiovascular protection with use of GLP-1RAs and the main mechanisms underlying this effect. Moreover, it looks into how the availability of upcoming dual and triple incretin receptor agonists might expand the possibility for cardiovascular protection in people with type 2 diabetes. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesHumansIncretinsHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Cardiovascular diseasesDiabetes mellitus, type 2GlucagonGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideHeart failureIncretinsReview

Substanzen

IncretinsHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. stefano.delprato@unipi.it.
  • Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy. stefano.delprato@unipi.it.

Förderung

  • Università di Pisa

Zitieren

APA

Solini, A., Tricò, D., & Del Prato, S. (2023). Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia, 66(10), 1820-1831. https://doi.org/10.1007/s00125-023-05973-w

Vancouver

Solini A, Tricò D, Del Prato S. Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia. 2023;66(10):1820-1831. doi:10.1007/s00125-023-05973-w

BibTeX
@article{Solini2023,
  author = {Solini, Anna and Tricò, Domenico and Del Prato, Stefano},
  title = {Incretins and cardiovascular disease: to the heart of type 2 diabetes?},
  journal = {Diabetologia},
  year = {2023},
  volume = {66},
  number = {10},
  pages = {1820--1831},
  doi = {10.1007/s00125-023-05973-w}
}
Kostenlos starten →